Press release



IBA Dosimetry delivers its 1,000th Blue Phantom² scanning system to the Centre de Radiothérapie des Ardennes in Charleville-Mézières, France

- Major milestone reached with the delivery of the 1,000th Blue Phantom²
- The Blue Phantom² scanning system enables effective Beam Commissioning & Annual QA with higher accuracy and a reduction in work time.
 - The sophistication of the Blue Phantom² scanning system allows for a smooth and simple workflow.

Schwarzenbruck, **Germany**, **April 3rd**, **2014** – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the delivery of its 1,000th Blue Phantom² system.

For over 40 years IBA Dosimetry has been developing high quality Dosimetry equipment and services, with more than 4,000 satisfied water phantom users worldwide.

IBA Dosimetry is continually striving for innovative solutions and services in order to constantly improve Dosimetry. The company embodies decades of expertise, research and experience in the development and clinical use of water phantom systems which includes their latest development, the Blue Phantom² system.

Dominique Belge, Centre de Radiothérapie des Ardennes, Charleville-Mézières, France said, "IBA Dosimetry's new Blue Phantom² scanning system is state-of-the-art. We have looked at different solutions on the market and have chosen the IBA system because of its proven accuracy, flexibility, long-term stability and reliability. After using it for the duration of my university career, I am very pleased to return to the Blue Phantom² system."

The Blue Phantom² system, along with the powerful scanning software OmniPro-Accept and the Common Control Unit (CCU), is the leading water phantom solution for radiation therapy (RT) beam scanning. The systems unique design facilitates faster and more accurate commissioning of RT treatment systems which is fundamental for safe patient treatments.

"I'm very excited that we have reached this milestone of 1,000 installed Blue Phantom² systems worldwide" said **Salih Arican, Product Manager at IBA Dosimetry.** "This milestone is testimony of the satisfaction of our loyal customers and users of IBA equipment. The Blue Phantom² on display at the IBA booth at the upcoming ESTRO meeting in Vienna, provides unique technology and benefits in Beam Commissioning & Annual QA.

-ENDS-

About IBA

IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company. IBA is the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy

Press release | April 3rd, 2014

Press release



solutions are scalable and adaptable, offering universal full scale proton therapy centres as well as next generation compact, single room systems.

IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety, as well as particle accelerators for medical and industrial applications.

Headquartered in Belgium and employing more than 1,000 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.

IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Contact:

Christian Neumeier Marketing Specialist

IBA Dosimetry GmbH Bahnhofstr. 5 90592 Schwarzenbruck, Germany

Tel.: +49 9128 607 0
Fax.: +49 9128 607 10
www.iba-dosimetry.com
dosimetry-info@iba-group.com

Press release | April 3rd, 2014